General
Preferred name
LOXAPINE
Synonyms
LOXAPINE SUCCINATE ()
CPD000058470 ()
Loxapac ()
Cloxazepin ()
Daxolin ()
Loxapine succinate salt ()
Loxapine (succinate) ()
LOXAPINE HYDROCHLORIDE ()
NSC 759578 ()
Loxitane ()
NSC-759578 ()
Loxapine ()
CL-71563 ()
CL 71563 ()
SUM 3170 ()
CL-62362 ()
Adasuve ()
Loxitane Intramuscular [as hydrochloride] ()
CL 62,362 ()
Loxitane-C Oral Suspension [as hydrochloride] ()
SUM-3170 ()
Loxitane C ()
Loxitane Im ()
Loxapine HCl ()
Loxapine-d8 ()
P&D ID
PD010043
CAS
27833-64-3
1977-10-2
56563-01-0
54810-23-0
1189455-63-7
Tags
natural product
drug
available
Approved by
FDA
First approval
1975
1976
Drug Status
approved
Drug indication
Schizophrenia
Tranquilizer (minor)
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Loxapine is a dibenzoxazepine class typical antipsychotic drug. (GtoPdb)
DESCRIPTION Dibenzoxazepine antipsychotic agent (LOPAC library)
DESCRIPTION Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.oxapine is a typical antipsychotic medication, used primarily in the treatment of schizophrenia. Trade names for loxapine taken by mouth include Loxapac and Loxitane; the inhalable form is approved as Adasuve. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
1
Compound Sets
32
Bioprocess diversity set
BOC Sciences Bioactive Compounds
loxapine-succinate-cas-27833-64-3-item-84-64949
Cayman Chemical Bioactives
20760
33537
ChEMBL Approved Drugs
CHEMBL1201155
CHEMBL831
CHEMBL1201060
ChEMBL Drugs
CHEMBL1201155
CHEMBL831
CHEMBL1201060
Concise Guide to Pharmacology 2017/18
205
Concise Guide to Pharmacology 2019/20
205
Concise Guide to Pharmacology 2021/22
205
Concise Guide to Pharmacology 2023/24
205
Drug Repurposing Hub
DrugBank
DB00408
DrugBank Approved Drugs
DB00408
DrugCentral
1613
DrugCentral Approved Drugs
1613
DrugMAP
DM8AI9U
DrugMAP Approved Drugs
DM8AI9U
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
205
Ki Database
LOXAPINE
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL831
MedChem Express Bioactive Compound Library
HY-17390A
HY-17390
NCATS Inxight Approved Drugs
LER583670J
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
loxapine-succinate
TargetMol Bioactive Compound Library
T1412
The Spectrum Collection
External IDs
73
Properties
(calculated by RDKit )
Molecular Weight
327.11
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
0
Ring Count
4
Aromatic Ring Count
2
cLogP
3.77
TPSA
28.07
Fraction CSP3
0.28
Chiral centers
0.0
Largest ring
7.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biological process
Glycosylation & protein folding/targeting, cell wall biogenesis
Pathway
GPCR/G protein
Neuroscience
Anti-infection
Neuronal Signaling
Target
5-HT2 (bovine)
5-HT2 (human)
D2
D4
ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4
5-HT Receptor
Bacterial
Dopamine Receptor
5-HT Receptor,Dopamine Receptor
Member status
virtual
MOA
Dopamine D4 Receptor Ligands
Dopamine D2 Antagonists
Dopamine D1 Receptor Ligands
Dopamine D3 Receptor Ligands
5-HT2 Antagonists
dopamine receptor antagonist, serotonin receptor antagonist
Indication
schizophrenia
Therapeutic Class
Antipsychotic Agents
Source data